文献速递血栓与止血

新冠疫苗接种后抗PF4/聚阴离子抗体阳性频率

Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2.
PubMed 文献 · Blood · 2021-01-01

本研究检测了281名健康受种者接种ChAdOx1 nCoV-19或BNT162b2后抗PF4/聚阴离子抗体阳性率,分别为8.0%和5.6%,总阳性率6.8%。阳性样本光密度值多较低,且无一在PF4存在下诱导血小板活化,提示低滴度阳性结果临床相关性有限。

要点

  • 接种ChAdOx1或BNT162b2后均可出现低滴度抗PF4/聚阴离子抗体阳性。
  • 阳性血清在PF4存在下未诱导血小板活化,致病性VITT抗体不常见。
  • 无症状接种者低滴度PF4/聚阴离子EIA阳性应谨慎解读。

核心结论

  • 接种mRNA和腺病毒载体新冠疫苗后均可出现抗PF4/聚阴离子EIA阳性,但多为低滴度且无血小板活化特性,临床相关性有限。

研究设计与样本

  • 研究纳入281名健康受种者,其中ChAdOx1 nCoV-19组138人,BNT162b2组143人,检测接种后抗PF4/聚阴离子抗体。

主要发现

  • 281人中19人抗PF4/聚阴离子抗体阳性,总阳性率6.8%(95%CI 4.4-10.3)。
  • BNT162b2组阳性率5.6%(95%CI 2.9-10.7),ChAdOx1 nCoV-19组阳性率8.0%(95%CI 4.5-13.7)。
  • 阳性样本光密度值多在0.5至1.0单位之间(参考范围<0.50)。
  • 所有PF4/聚阴离子EIA阳性样本在PF4存在下均未诱导血小板活化。

临床怎么用

  • 无症状接种者低滴度PF4/聚阴离子EIA阳性结果应谨慎解读,避免过度诊断VITT。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vaccination using the adenoviral vector COVID-19 vaccine ChAdOx1 nCoV-19 (AstraZeneca) has been associated with rare vaccine-induced immune thrombotic thrombocytopenia (VITT). Affected patients test strongly positive in platelet factor 4 (PF4)/polyanion enzyme immunoassays (EIAs), and serum-induced platelet activation is maximal in the presence of PF4. We determined the frequency of anti-PF4/polyanion antibodies in healthy vaccinees and assessed whether PF4/polyanion EIA+ sera exhibit platelet-activating properties after vaccination with ChAdOx1 nCoV-19 (n = 138) or BNT162b2 (BioNTech/Pfizer; n = 143). In total, 19 of 281 participants tested positive for anti-PF4/polyanion antibodies postvaccination (All: 6.8% [95% confidence interval (CI), 4.4-10.3]; BNT162b2: 5.6% [95% CI, 2.9-10.7]; ChAdOx1 nCoV-19: 8.0% [95% CI, 4.5% to 13.7%]). Optical densities were mostly low (between 0.5 and 1.0 units; reference range, <0.50), and none of the PF4/polyanion EIA+ samples induced platelet activation in the presence of PF4. We conclude that positive PF4/polyanion EIAs can occur after severe acute respiratory syndrome coronavirus 2 vaccination with both messenger RNA- and adenoviral vector-based vaccines, but many of these antibodies likely have minor (if any) clinical relevance. Accordingly, low-titer positive PF4/polyanion EIA results should be interpreted with caution when screening asymptomatic individuals after vaccination against COVID-19. Pathogenic platelet-activating antibodies that cause VITT do not occur commonly following vaccination.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Thiele T, Ulm L, Holtfreter S, et al. Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2. Blood. 2021. PMID: 33988688. doi:10.1182/blood.2021012217

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。